Skip to content
777 Sourcing.

Capability

vaccine adjuvant development

Suppliers
2
States & provinces
2
Countries
1

2 vaccine adjuvant development suppliers across 2 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

AURAVAX THERAPEUTICS, INC.

HOUSTON, TX

AuraVax Therapeutics, Inc. is commercializing its intranasal platform called NanoSTING to treat and prevent respiratory infections independent of the pathogen. NanoSTING technology activates the STING pathway to restore and boost innate immunity. The company is developing its technology as a new class of host-directed-therapeutics to treat infections from respiratory pathogens, and is also pursuing NanoSTING to improve intranasal vaccines.

host-directed therapeuticsintranasal drug development

Compiled from public sources

CLARUS BIOLOGICS, INC

MORRISVILLE, NC

Clarus Biologics is dedicated to the discovery and development of novel vaccine and immunology technologies. Launched in Q4 2019, its lead product is CBI-3A, a next-generation Virus Like Particle (VLP) vaccine adjuvant that elicits immune responses from all three elements of the adaptive immune system and has been studied in multiple animal species.

licensingpre-clinical studiesprotein productionVLP technology

Compiled from public sources

Related capabilities

Other processes offered by the shops that list vaccine adjuvant development.

Browse all capabilities